Alpa Laboratories

Alpa Laboratories EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Alpa Laboratories (ALPA.NS) as of Oct 17, 2026 is 48.04 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 81.06 M INR — a change of -40.74% (lower).

EBITDA

48.04 MINR

YoY

-40.74%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Alpa Laboratories is 2025 48.04 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Alpa Laboratories was 2024 81.06 M INR. It decreases by -40.74% lower compared to the previous year.

The Alpa Laboratories EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
39.23 M INR
Jan 1, 2019
11.46 M INR
Jan 1, 2020
33.51 M INR
Jan 1, 2021
76.98 M INR
Jan 1, 2022
106.64 M INR
Jan 1, 2023
80.75 M INR
Jan 1, 2024
81.06 M INR
Jan 1, 2025
48.04 M INR
The Alpa Laboratories EBITDA history
YEAREBITDAYoY
48.04 MINR-40.74%
81.06 MINR+0.39%
80.75 MINR-24.28%
106.64 MINR+38.53%
76.98 MINR+129.70%
33.51 MINR+192.38%
11.46 MINR-70.78%
39.23 MINR-21.38%
49.90 MINR-26.94%
68.30 MINR+99.67%
34.21 MINR-40.41%
57.41 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alpa Laboratories Stock analysis

What does Alpa Laboratories do? Alpa Laboratories Ltd is a pharmaceutical company headquartered in Indore, India, with 318 employees. It operates in the Health Care sector within the Pharmaceuticals industry. The company went public on August 1, 2007. Its product range includes generic and over-the-counter drugs for human and veterinary use, such as capsules, creams, gels, ointments, ear and eye drops, and tablets. Human products feature Ampicillin Capsule, Amoxycillin Trihydrate Capsule, and Paracetamol Tablet, while veterinary products include Alpamin Bolus and Atropine Inj. B.Vet.C. Alpa Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpa Laboratories stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Alpa Laboratories is 48.04 M INR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Alpa Laboratories changed from 81.06 M INR to 48.04 M INR, representing a -40.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Alpa Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Alpa Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Alpa Laboratories

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Alpa Laboratories